News Releases

5-Year Real-World Safety and Efficacy Data from On-X Aortic Heart Valve Low INR Post-Market Study Demonstrate Even Better Patient Outcomes Than Predicted by the PROACT IDE Study Late-Breaking 30-Day Data from AMDS PERSEVERE Trial Demonstrate Positive Aortic Remodeling Outcomes and Zero DANE Tears

ATLANTA , April 22, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2024 financial results will be released on Monday, May 6, 2024 after the market closes.

ATLANTA , April 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT),  a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming 23 rd Annual Needham Virtual Healthcare Conference .

ATLANTA , March 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT),  a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 34 th Annual Healthcare MedTech & Services Conference .

Fourth Quarter and Recent Business Highlights: Achieved revenue of $93.7 million in the fourth quarter of 2023 versus $79.4 million in the fourth quarter of 2022, an increase of 18% on a GAAP basis and 15% on a non-GAAP constant currency basis Achieved revenue of $354.0 million for the full year of

ATLANTA , Feb. 1, 2024 /PRNewswire/ --   Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2023 financial results will be released on Thursday, February 15, 2024 after the market closes.

Full IDE Data Set Demonstrates Statistically Significant Reduction of All-Cause Mortality and Primary Major Adverse Events (MAEs) at 30 days with use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion 72% Reduction in All-Cause Mortality and 52% Reduction in Primary

Non-Dilutive Financing Provides Comprehensive Solution to Address Debt Maturities  and Provide Flexibility to Further Optimize Capital Structure ATLANTA , Jan. 18, 2024 /PRNewswire/ -- Artivion, Inc.   (NYSE: AORT) , a leading cardiac and vascular surgery company focused on aortic disease, today